

AstraZeneca and Francis Crick Institute sign research agreement

24 May 2017 | News

The new partnership will also offer Crick researchers access to AstraZeneca compounds and a range of technology platforms.



The Francis Crick Institute has signed a new research agreement with global biopharmaceutical company AstraZeneca. The five-year initiative will see researchers from AstraZeneca and the Crick collaborate on early-stage research that could translate into new treatments and health innovations in the future.

The combination of AstraZeneca's expertise in developing new medicines and the Crick's strength in discovery science will maximize the potential to make breakthroughs neither partner could alone. The joint goal is to stimulate and accelerate basic research into the understanding of human health across a range of cancers, cardiovascular and respiratory diseases.

The new partnership will also offer Crick researchers access to AstraZeneca compounds and a range of technology platforms. Crick projects that receive funding through the partnership could see scientists from AstraZeneca join the team at the Crick and vice versa. Knowledge exchange between participants will be at the heart of the collaboration, and it will create opportunities for postdoctoral researchers in both industry and academia to learn from each other.

Accelerating translation for health and wealth is one of the Crick's strategic priorities and this new agreement with AstraZeneca reflects that goal.